111 related articles for article (PubMed ID: 18487909)
21. Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors.
Eisenberg BL
Oncology (Williston Park); 2003 Nov; 17(11):1615-20; discussion 1620, 1623, 1626 passim. PubMed ID: 14682111
[TBL] [Abstract][Full Text] [Related]
22. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
23. Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib.
Schindler CG; Armbrust T; Gunawan B; Langer C; Füzesi L; Ramadori G
Z Gastroenterol; 2005 Mar; 43(3):267-73. PubMed ID: 15765299
[TBL] [Abstract][Full Text] [Related]
24. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
25. [A case of recurrent duodenal gastrointestinal stromal tumor resistant to imatinib and sunitinib, successfully treated with regorafenib].
Takeda Y; Nakahira S; Katsura Y; Ohmura Y; Kusama H; Kuroda Y; Goto T; Hashimoto T; Kimura K; Matsushita K; Sato Y; Morimoto Y; Ishida T; Nitta K; Kagawa Y; Okishiro M; Takeno A; Sakisaka H; Taniguchi H; Egawa C; Ohzono K; Nakatsuka S; Kato T; Tamura S
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1545-7. PubMed ID: 25731247
[TBL] [Abstract][Full Text] [Related]
26. [Consensus on the medical treatment of gastrointestinal stromal tumors].
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
[No Abstract] [Full Text] [Related]
27. Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy.
Van Looy T; Wozniak A; Floris G; Sciot R; Li H; Wellens J; Vanleeuw U; Fletcher JA; Manley PW; Debiec-Rychter M; Schöffski P
Clin Cancer Res; 2014 Dec; 20(23):6071-82. PubMed ID: 25316817
[TBL] [Abstract][Full Text] [Related]
28. 'Time is a GIFT in GIST'--the medical and paramedical perspective of a case with metastatic gastrointestinal stromal tumor.
Sevinc A; Camci C
Chemotherapy; 2009; 55(1):11-4. PubMed ID: 18974643
[TBL] [Abstract][Full Text] [Related]
29. Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy.
Jamali FR; Darwiche SS; El-Kinge N; Tawil A; Soweid AM
Oncologist; 2007 Apr; 12(4):438-42. PubMed ID: 17470686
[TBL] [Abstract][Full Text] [Related]
30. Adherence to imatinib therapy in patients with gastrointestinal stromal tumors.
Blay JY; Rutkowski P
Cancer Treat Rev; 2014 Mar; 40(2):242-7. PubMed ID: 23931926
[TBL] [Abstract][Full Text] [Related]
31. [Imatinib--a breakthrough in the treatment of gastrointestinal stromal tumors (GIST)].
Larsen JB
Ugeskr Laeger; 2003 Sep; 165(37):3503-7. PubMed ID: 14531349
[TBL] [Abstract][Full Text] [Related]
32. Practical aspects of managing gastrointestinal stromal tumors.
Sleijfer S; Seynaeve C; Wiemer E; Verweij J
Clin Colorectal Cancer; 2006 Nov; 6 Suppl 1():S18-23. PubMed ID: 17101064
[TBL] [Abstract][Full Text] [Related]
33. [The role of pathologists in the target therapy of gastrointestinal tumors].
Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2010 Jul; 39(7):433-5. PubMed ID: 21055169
[No Abstract] [Full Text] [Related]
34. F-18 FDG PET for assessing tyrosine kinase-related signal transduction inhibition in a GIST c-kit-positive tumor patient by imatinib.
Zaknun JJ; Kendler D; Moncayo R; zur Nedden D; Virgolini I
Clin Nucl Med; 2005 Nov; 30(11):749-51. PubMed ID: 16237304
[No Abstract] [Full Text] [Related]
35. Pharmacotherapy of gastrointestinal stromal tumours.
Eisenberg BL; von Mehren M
Expert Opin Pharmacother; 2003 Jun; 4(6):869-74. PubMed ID: 12783584
[TBL] [Abstract][Full Text] [Related]
36. Tyrosine kinase inhibitor-induced macrocytosis.
Schallier D; Trullemans F; Fontaine C; Decoster L; De Greve J
Anticancer Res; 2009 Dec; 29(12):5225-8. PubMed ID: 20044640
[TBL] [Abstract][Full Text] [Related]
37. [Gastrointestinal stromal tumors localized in small intestine and diagnosed preoperatively as gynecological neoplasms].
Zbigniew N; Piotr R; Bogusław L; Wanda M; Włodzimierz R
Ginekol Pol; 2005 Nov; 76(11):855-62. PubMed ID: 16566359
[TBL] [Abstract][Full Text] [Related]
38. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors.
Frolov A; Chahwan S; Ochs M; Arnoletti JP; Pan ZZ; Favorova O; Fletcher J; von Mehren M; Eisenberg B; Godwin AK
Mol Cancer Ther; 2003 Aug; 2(8):699-709. PubMed ID: 12939459
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant imatinib for borderline resectable GIST.
Koontz MZ; Visser BM; Kunz PL
J Natl Compr Canc Netw; 2012 Dec; 10(12):1477-82; quiz 1482. PubMed ID: 23221786
[TBL] [Abstract][Full Text] [Related]
40. Nanoneoadjuvant therapy of gastrointestinal stromal tumor (GIST).
DeMatteo RP
Ann Surg Oncol; 2009 Apr; 16(4):799-800. PubMed ID: 19169754
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
